CYCLOPHARM LIMITED

cyclo pharm

==> picture [43 x 55] intentionally omitted <==

30 September 2019

The Manager Company Announcements Office Australian Securities Exchange Limited 20 Bridge Street Sydney NSW 2000

Cyclopharm Ltd ABN 74 116 931 250 Unit 4, 1 The Crescent Kingsgrove NSW 2208 Australia T 61 2 9541 0411 F 61 2 9543 0960 www.cyclopharm.com.au

CYCLOPHARM STRENGTHENS LEADERSHIP TEAM

New senior leadership appointments strengthen sales, service and regulatory compliance
Timely appointments ‐ approaching anticipated FDA approval for Technegas[TM] sales in US market
US Sales for Technegas[TM] expected in 2020

Cyclopharm Limited (ASX: CYC) is pleased to announce four management appointments. Commenting on the appointments, Cyclopharm Managing Director and CEO, Mr. James McBrayer, said, “We have added a group of very high‐quality individuals to our team which will significantly strengthen our global compliance, sales and service capabilities, supporting the next phase of growth at Cyclopharm.”

“Specifically, we have greatly enhanced our quality and compliance capabilities through the hiring of Dr Mark Doverty to lead our global regulatory compliance and clinical research efforts. As part of our leadership team, Mark will leverage his expertise and track record as the former Head of the Office of Manufacturing Quality at the Australian Government’s Therapeutic Goods Administration to ensure our products and manufacturing practices remain at the forefront of regulatory best practice. Mark will also be responsible for ensuring our research efforts continue to support our entry into new markets for Technegas[TM] and enhance our sales into existing markets as clinical applications evolve.”

“As we have previously discussed, the US market is a significant near‐term opportunity to rapidly grow our sales of Technegas[TM] . As we approach the anticipated USFDA approval to commence marketing Technegas[TM] in the USA, we have focused on ensuring Cyclopharm has the right people, capabilities and processes to quickly take advantage of this opportunity, while continuing to grow our sales and service capabilities in existing markets.”

“The new hires, announced today, will support our goal of delivering initial sales and high‐quality customer service in the United States market in 2020 as well as driving the company’s strategy in the use of Technegas[TM] in indications beyond pulmonary embolism throughout the 57 countries where Technegas[TM] is currently sold.”

The company has appointed:

 Dr. Mark Doverty as the Global Head of Regulatory Compliance and Clinical Research. Dr. Doverty joins the senior executive team with a Doctorate in Pharmacology and a distinguished career in healthcare and therapeutic goods regulation. Dr Doverty was formerly the Head of the Office of Manufacturing Quality at the Australian Government’s Therapeutic Goods Administration.

Page 1 of 2

CYCLOPHARM STRENGTHENS LEADERSHIP TEAM continued…

 Niamh McAree as Head of Quality and Regulatory

Ms McAree has extensive international experience in medical device and pharmaceutical manufacturing compliance with both Merck and Terumo. Most recently she consulted to Cyclopharm supporting the development of the company’s Quality Management System, responding to the recent successful ISO and MDSAP audits.

 Sally‐Ann Cornelius as Head of Sales

Ms Cornelius is a specialist Molecular Imaging business development, sales and marketing professional with 20 years’ experience working in Nuclear Medicine and Molecular Imaging. Sally‐ Ann gained her experience with companies such as Global Medical Solutions and most recently Bayer Radiology, (formally Imaxeon), as Head of Molecular Imaging ANZ.

 Chris Quinn as Head of Service

Following a career in the Royal Australian Navy maintaining combat systems, Mr Quinn first began working with medical devices in 2005 with Gammasonics. Chris then went on to create a service division at Global Medical Solutions Australia. In 2013, Chris moved to Bayer Radiology ANZ (formerly Imaxeon) to assist in building its Molecular Imaging division.

For more information, please contact:

Mr James McBrayer Managing Director, CEO and Company Secretary Cyclopharm Limited T: +61 (02) 9541 0411

Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company’s mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas[TM] used in functional lung ventilation imaging.

Technegas[TM]

The Technegas[TM] technology is a structured ultra‐fine dispersion of radioactive labelled carbon, produced by using dried Technetium‐99m in a carbon crucible, micro furnaced for a few seconds at around 2,700[o] C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas[TM] , together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other disease states to include COPD, asthma, pulmonary hypertension and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.

Page 2 of 2

AI assistant

CYCLOPHARM LIMITED Board/Management Information 2019